Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1373775

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1373775

Global Glioblastoma Multiforme Treatment Market Size, Share, Growth Analysis, By Type(Surgery, Radiation Therapy), By Application(Newly Diagnosed glioblastoma multiforme treatment, Recurrent glioblastoma multiforme treatment) - Industry Forecast 2023-2030

PUBLISHED:
PAGES: 157 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global Glioblastoma Multiforme Treatment Market size was valued at USD 2.3 billion in 2021 and is poised to grow from USD 2.5 billion in 2022 to USD 4.95 billion by 2030, growing at a CAGR of 8.9% in the forecast period (2023-2030).

The global market for glioblastoma multiforme treatment has witnessed substantial growth in recent years, driven by the increasing incidence of glioblastoma multiforme treatment cases worldwide and the growing demand for effective treatment options. The increasing incidence of glioblastoma multiforme treatment, coupled with the limited treatment options available, has created a pressing need for innovative and effective therapies, thereby fueling market growth. Advancements in medical research and technology have contributed to the development of novel treatment modalities for glioblastoma multiforme treatment. The market has witnessed a shift towards personalised medicine approaches, with a focus on targeted therapies and immunotherapies. Targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibodies, aim to disrupt specific molecular pathways involved in glioblastoma multiforme treatment progression. Immunotherapies, including immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, harness the body's immune system to recognize and destroy cancer cells. These advancements have significantly improved treatment outcomes and have spurred the growth of the glioblastoma multiforme treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Glioblastoma Multiforme Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glioblastoma Multiforme Treatment Market Segmental Analysis

The global glioblastoma multiforme treatment market is segmented by type, application, and region. Based on type, the market can be segmented into Surgery, Radiation Therapy, Chemotherapy and Targeted Therapy. Based on application, the market is segmented into Newly Diagnosed glioblastoma multiforme treatment, Recurrent glioblastoma multiforme treatment, Palliative Care, Clinical Trials and Paediatric glioblastoma multiforme treatment. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Glioblastoma Multiforme Treatment Market

Increasing Incidence of Glioblastoma Multiforme

  • The increasing occurrence of glioblastoma multiforme, an aggressive brain cancer, is a significant driver of the market. As the prevalence of glioblastoma multiforme treatment continues to rise worldwide, there is a growing need for the development of effective treatment options. This drives the demand for glioblastoma multiforme treatment treatments and fuels market growth.

Restraints in the Global Glioblastoma Multiforme Treatment Market

High Treatment Costs

  • The cost of glioblastoma multiforme treatment poses a financial burden for patients, primarily due to the expenses associated with surgery, radiation therapy, chemotherapy, and supportive care. The high treatment costs can impede patient access to advanced therapies and impact the affordability of treatments. Furthermore, reimbursement policies play a crucial role in determining patient access to these treatments, thereby influencing market growth.

Market Trends of Global Glioblastoma Multiforme Treatment Key

  • Increasing Use of Targeted Therapies: Targeted therapies are designed to target specific molecules involved in the growth and spread of glioblastoma multiforme treatment cells. These therapies have shown promise in improving the survival rates of patients with glioblastoma multiforme treatment.
  • Development of New Immunotherapies: Immunotherapies are designed to boost the body's immune system to fight cancer cells. These therapies are still in the early stages of development, but they have shown promise in treating glioblastoma multiforme treatment.
  • The Increasing Demand for Personalised treatment: Personalised treatment is tailored to the individual patient's tumour profile. This approach has the potential to improve the efficacy and safety of treatment for glioblastoma multiforme treatment patients.
Product Code: SQMIG35D2105

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
    • Regulatory Landscape
    • Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact
  • Global Glioblastoma Multiforme Treatment Market by Type
    • Market Overview
    • Surgery
    • Radiation Therapy
    • Chemotherapy
    • and Targeted Therapy.
  • Global Glioblastoma Multiforme Treatment Market by Application
    • Market Overview
    • Newly Diagnosed glioblastoma multiforme treatment
    • Recurrent glioblastoma multiforme treatment
    • Palliative Care
    • Clinical Trials and Pediatric glioblastoma multiforme treatment.
  • Global Glioblastoma Multiforme Treatment Market Size by Region
    • Market Overview
    • North America
  • USA
  • Canada
    • Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
    • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
    • Latin America
  • Brazil
  • Rest of Latin America
    • Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
  • By Development
  • By Company
  • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Tocagen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Kazia Therapeutics Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • DelMar Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Arbor Pharmaceuticals, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • BTG International Ltd (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Mundipharma International Limited (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Northwest Biotherapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Orbus Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • VBL Therapeutics (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • GT Medical Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Oncolys Biopharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Tocagen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • ValiRx Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!